Abstract
Individuals with type 2 diabetes (T2D) and dyslipidemia are at an increased risk of cardiovascular disease. Fibrates are a class of drugs prescribed to treat dyslipidemia, but variation in response has been observed. To evaluate common and rare genetic variants that impact lipid responses to fenofibrate in statin‐treated patients with T2D, we examined lipid changes in response to fenofibrate therapy using a genomewide association study (GWAS). Associations were followed‐up using gene expression studies in mice. Common variants in SMAD3 and IPO11 were marginally associated with lipid changes in black subjects (P < 5 × 10‐6). Rare variant and gene expression changes were assessed using a false discovery rate approach. AKR7A3 and HSD17B13 were associated with lipid changes in white subjects (q < 0.2). Mice fed fenofibrate displayed reductions in Hsd17b13 gene expression (q < 0.1). Associations of variants in SMAD3, IPO11, and HSD17B13, with gene expression changes in mice indicate that transforming growth factor‐beta (TGF‐β) and NRF2 signaling pathways may influence fenofibrate effects on dyslipidemia in patients with T2D.
Document Type
Article
Publication Date
4-2018
Digital Object Identifier (DOI)
https://doi.org/10.1002/cpt.798
Funding Information
This research was supported by a National Heart, Lung, and Blood Institute grant to the University of North Carolina at Chapel Hill (5R01HL110380-04) and R01 HL110400 to the Joslin Diabetes Center and the University of Virginia. Dr Ginsberg received support from National Heart, Lung, and Blood Institute R01 HL110418.
Related Content
Additional Supporting Information may be found in the online version of this article.
Repository Citation
Rotroff, Daniel M.; Pijut, Sonja S.; Marvel, Skylar W.; Jack, John R.; Havener, Tammy M.; Pujol, Aurora; Schluter, Agatha; Graf, Gregory A.; Ginsberg, Henry N.; Shah, Hetal S.; Gao, He; Morieri, Mario-Luca; Doria, Alessandro; Mychaleckyi, Josyf C.; McLeod, Howard L.; Buse, John B.; Wagner, Michael J.; Motsinger-Reif, Alison A.; and ACCORD/ACCORDion Investigators, "Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes" (2018). Pharmaceutical Sciences Faculty Publications. 119.
https://uknowledge.uky.edu/ps_facpub/119
Supporting Information
Included in
Genetics and Genomics Commons, Pharmacology Commons, Pharmacy and Pharmaceutical Sciences Commons, Therapeutics Commons
Notes/Citation Information
Published in Clinical Pharmacology & Therapeutics, v. 103, issue 4, p. 712-721.
© 2017 American Society for Clinical Pharmacology and Therapeutics
The copyright holder has granted the permission for posting the article here.
The document available for download is the authors' post-peer-review final draft of the article.